1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>Germany

Germany May Make Drug Prices Confidential In AMNOG Update

 
• By Francesca Bruce

Under forthcoming changes to the law, companies could gain confidential pricing in Germany, which could make it easier to defend a higher price in other countries. But sponsor of some orphan products may face a rockier path to market.

German flag

Price transparency in Germany, which has had a knock on effect on prices elsewhere in the world thanks to global reference pricing, could soon be no more thanks to expected changes to the AMNOG law.

AMNOG regulates the nation's drug pricing and reimbursement system and changes are to be detailed in a first draft of a new bill that could be published by the end of the month, says Alexander Natz, secretary general of EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs. The law took affect Jan

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Germany

More from Europe

EMA Explores Using AI Language Models To Refine Oncology Guidance

 
• By Vibha Sharma

The European Medicines Agency has for the first time explicitly stated it is considering the use of large language models as a tool to improve the readability of a scientific guideline.

Industry On Making England’s HTA Innovation Lab A Success

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.

International Group Aims To Shape The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.